<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by CUBE @UCLA on Medium]]></title>
        <description><![CDATA[Stories by CUBE @UCLA on Medium]]></description>
        <link>https://medium.com/@cube.ucla?source=rss-e7d22e79faf3------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*cuBaRvlygF7ngqfAhY-nmw.jpeg</url>
            <title>Stories by CUBE @UCLA on Medium</title>
            <link>https://medium.com/@cube.ucla?source=rss-e7d22e79faf3------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 23:43:20 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@cube.ucla/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Why Does Access to Healthcare Depend on Your Race?]]></title>
            <link>https://medium.com/@cube.ucla/why-does-access-to-healthcare-depend-on-your-race-3e3e20a35c2d?source=rss-e7d22e79faf3------2</link>
            <guid isPermaLink="false">https://medium.com/p/3e3e20a35c2d</guid>
            <category><![CDATA[insurance]]></category>
            <category><![CDATA[accessibility]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[racial-disparities]]></category>
            <category><![CDATA[boston-scientific]]></category>
            <dc:creator><![CDATA[CUBE @UCLA]]></dc:creator>
            <pubDate>Fri, 08 Jan 2021 00:48:37 GMT</pubDate>
            <atom:updated>2021-01-08T00:48:37.585Z</atom:updated>
            <content:encoded><![CDATA[<h4>Healthcare Disparities in the US and How One Company Is Addressing Them</h4><h4>By Sanah Ali</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/640/0*dRCZttsGwo_C984H" /><figcaption>Source: <a href="https://drnsmusings.files.wordpress.com/2014/03/corbis-42-34669850.jpeg">corbis-42–34669850.jpeg</a></figcaption></figure><p>This past summer, the killing of George Floyd reminded Americans of the racial inequalities that still plague our country. This inequality is particularly evident in the healthcare system. National data collected over the past 50 years shows that although life expectancy rates for both Black and white Americans have increased, life expectancy rates for Black Americans is still much lower than their white counterparts. One reason for this difference in expectancy rates is that Blacks and other people of color do not have the same access to health care as whites do. These disparities in health care stem from systematic racism and are exhibited through cost barriers, lack of representation, and accessibility to health services.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*Mp-G48nkcaze3gLz" /><figcaption>Source: <a href="https://www.usnews.com/news/blogs/data-mine/2015/01/05/black-americans-have-fewer-years-to-live-heres-why">https://www.usnews.com/news/blogs/data-mine/2015/01/05/black-americans-have-fewer-years-to-live-heres-why</a></figcaption></figure><h3><strong>Barriers to Equal Health Care</strong></h3><h4><strong>Cost as a Barrier</strong></h4><p>The cost of a broken arm without insurance would be over $1,200. Many Americans cannot afford this additional and unexpected expense. 2020 unemployment rates for Blacks was 11.5% and 9.9% for Hispanics or Latinos, compared to 7.1% for Whites. The higher unemployment rates for people of color constitute a significant barrier to affording health care.</p><p>Additionally, the median household income was $68,145 for whites, but only $50,486 and $40,258 for Hispanics and Blacks respectively. This stark difference further shows how affording health care is significantly more difficult for people of color.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/800/0*bYLtlqe2vXn0Nup0" /><figcaption>Source: <a href="https://www.census.gov/content/dam/Census/library/visualizations/2018/demo/p60-263/figure1.pdf">https://www.census.gov/content/dam/Census/library/visualizations/2018/demo/p60-263/figure1.pdf</a></figcaption></figure><p>For many Americans, health insurance is available through their employer, making it easy and accessible. However, this is not the case for people of color. 66% of whites have employer-sponsored insurance, but only 46% of Blacks and 41% of Hispanic or Latinos do, leaving the majority of people of color with no health insurance. Although widely available, health insurance is not easily accessible to minorities and people of color due to the high costs and the inequity of employment opportunities.</p><h4><strong>Lack of Minority Representation in the Healthcare System</strong></h4><p>Another factor contributing to the disparities in healthcare is the lack of minority representation in health care providers. Physicians in the United States are 67% white, but only 6.3% Hispanic and 4.8% Black. Similarly, Registered Nurses are 73.5% white, but only 5.7% Hispanic and 10.4% Black. The percent of white health providers does not adequately represent the true makeup of the population. Therefore patients are often seen by providers they cannot relate to. This further perpetuates the inequity by creating distrust between the patient and provider. The lack of representation of people of color is also evident in federal and state policymakers, medical corporation leadership, hospital administration, pharmaceuticals, and insurance companies.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/450/0*tWgaCUyYT2oBlqSD" /><figcaption>Source: <a href="https://www.sciencemag.org/news/2016/04/white-doctors-might-underestimate-their-black-patients-pain">https://www.sciencemag.org/news/2016/04/white-doctors-might-underestimate-their-black-patients-pain</a></figcaption></figure><h4><strong>Health Care Accessibility</strong></h4><p>Consistent accessibility is another significant factor in the disparity in health care. Regular access to a health care provider or facility leads to improved health care. However, for Blacks and people of color, this can be difficult as cost and health insurance coverage may dictate whether they seek regular and preventative health care or simply seek it when necessary. Trust between patient and provider is also a deciding factor of whether Blacks and people of color seek preventative and follow-up care. This trust is built when patients can relate to their providers both racially and culturally. If a patient can find a provider that they can relate to they are more likely to receive proper and adequate care.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*Gp3i-x6smoRw7T5Q" /><figcaption>Source: <a href="https://www.starmedicalassociates.com/2020/08/21/6-reasons-you-should-get-your-wellness-exam-annually/">https://www.starmedicalassociates.com/2020/08/21/6-reasons-you-should-get-your-wellness-exam-annually/</a></figcaption></figure><h3><strong>Impacts</strong></h3><p>These inequities all have a drastic impact on the overall health and wellbeing of minorities. These health care barriers lead to unmet health needs, lack of preventative care, lack of medical treatments, financial burdens, and decreased accessibility to medication. All of these impacts culminate in the overall poor quality of health care.</p><h3><strong>Striving to “Close the Gap”</strong></h3><p>Although this issue is far from being solved, one company has taken steps to address it. Boston Scientific, the Massachusetts-based company that develops medical devices, is using data to highlight inequities in health care. They initiated a program to help fight inequality in health care in racially diverse communities. Shortly after the killing of George Floyd in Minneapolis, Boston Scientific’s CEO, Michael Mahoney issued a letter condemning racism, and the company committed $2.5 million towards combating it. The company also renewed its Close the Gap program. Close the Gap aims to provide hospitals and physicians with the data necessary to ensure patients get the treatment they need. The program currently focuses on cardiovascular and peripheral vascular diseases but the intent is to include colorectal cancer and neuromodulation in the future.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/770/0*7-wBVtLQfByqAG5k" /><figcaption>Source: <a href="https://www.mddionline.com/cardiovascular/boston-scientific-takes-systemic-racism">https://www.mddionline.com/cardiovascular/boston-scientific-takes-systemic-racism</a></figcaption></figure><p>The program utilizes a repository of data where Boston Scientific can look at an area by zip code and provide education to both providers and patients on diseases such as heart failure, atrial fibrillation, and stroke. Education for patients includes therapies and possible treatments. Once providers and hospital systems have this data they can then work directly in their own local communities to address those issues specifically.</p><p>In a recent interview, Camille Chang Gilmore, VP of Human Resources and Global Chief Diversity Officer, discusses how the program can be effective in a post-COVID-19 strategy to help build back trust in racially diverse communities especially predominantly Black, Hispanic communities. Gilmore describes Boston Scientific’s mission with this program, “We are here to improve the health care outcomes for all patients around the world”.</p><h3></h3><p>Read how we&#39;re equipping hospitals and healthcare providers with tools to address systemic racism in @MDDIonline: https://t.co/1gEmcIDRTM</p><p>This initiative is an important step in addressing the health care disparities we see today. Although far from over, Boston Scientific and its initiative can serve as an example of how to fight and rectify health care inequities. As we look to improve the future of healthcare, other companies should look to follow this example.</p><p>Sources:</p><ul><li><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4194634/">Understanding and Addressing Racial Disparities in Health Care</a></li><li><a href="https://www.bls.gov/web/empsit/cpsee_e16.htm">E-16. Unemployment rates by age, sex, race, and Hispanic or Latino ethnicity</a></li><li><a href="https://www.businessinsider.com/how-healthcare-and-insurance-work-around-the-world-2017-7">Here&#39;s what would happen if you broke your arm in 9 countries around the world</a></li><li><a href="https://www.americanbar.org/groups/crsj/publications/human_rights_magazine_home/health-matters-in-elections/racial-and-ethnic-disparities-in-employer-sponsored-health-coverage/">Racial and Ethnic Disparities in Employer-Sponsored Health Coverage</a></li><li><a href="https://www.medicaldesignandoutsourcing.com/how-boston-scientific-can-help-close-the-gap-in-healthcare/">How Boston Scientific can help close the gap in healthcare | Medical Design and Outsourcing</a></li></ul><p><a href="https://bhw.hrsa.gov/sites/default/files/bhw/nchwa/diversityushealthoccupations.pdf">https://bhw.hrsa.gov/sites/default/files/bhw/nchwa/diversityushealthoccupations.pdf</a></p><iframe src="https://drive.google.com/viewerng/viewer?url=https%3A//www.bostonscientific.com/content/dam/bostonscientific/endo/general/gastro-specialty/ENDO-Close-the-Gap-Fact-Sheet.pdf&amp;embedded=true" width="600" height="780" frameborder="0" scrolling="no"><a href="https://medium.com/media/e5cb698140182b4a0da940c5c02d3160/href">https://medium.com/media/e5cb698140182b4a0da940c5c02d3160/href</a></iframe><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=3e3e20a35c2d" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[An Overview of Switzerland’s Healthcare System]]></title>
            <link>https://medium.com/@cube.ucla/an-overview-of-switzerlands-healthcare-system-bbd7f6fcc14b?source=rss-e7d22e79faf3------2</link>
            <guid isPermaLink="false">https://medium.com/p/bbd7f6fcc14b</guid>
            <category><![CDATA[reform]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[universal-healthcare]]></category>
            <category><![CDATA[switzerland]]></category>
            <dc:creator><![CDATA[CUBE @UCLA]]></dc:creator>
            <pubDate>Fri, 08 Jan 2021 00:36:54 GMT</pubDate>
            <atom:updated>2021-01-08T00:36:54.107Z</atom:updated>
            <content:encoded><![CDATA[<h4><em>What it looks like and why it works</em></h4><h4>By Rahil Modi</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/415/0*PGGICLHApkw-Pzma" /><figcaption>Source: <a href="http://header image from freewebheaders.com">freewebheaders.com</a></figcaption></figure><p>The COVID-19 pandemic has upended daily life worldwide. Millions lost their jobs, beloved businesses shut down, and families mourned the loss of their loved ones. Additionally, the pandemic has highlighted the many avoidable problems that plague the American healthcare system, including (but not limited to) high costs and health insurance being tied to employment. Unsurprisingly, US News ranks the United States <a href="https://www.usnews.com/news/best-countries/slideshows/countries-with-the-most-well-developed-public-health-care-system?slide=2">outside the top 10 countries</a> in the world for healthcare. Seeing this begs the question of what policies other countries have implemented to build a healthcare system that works for their people best while also bolstering their economy. One such country is Switzerland, which has a universal, privatized model.</p><h4><strong>What does Switzerland’s healthcare system look like?</strong></h4><p>In response to rising healthcare costs and inequality, Switzerland passed LAMal, a major healthcare reform bill, in 1996 with <a href="https://pnhp.org/news/oecdwho-report-on-the-swiss-health-system/#:~:text=In%201996%2C%20Switzerland%20implemented%20the,and%20guaranteeing%20high%2Dquality%20coverage.">the three goals of strengthening solidarity, containing costs and spending, and guaranteeing high-quality coverage</a>. The law requires that all citizens purchase health insurance from a private insurer, and those who cannot afford the basic plan receive tax-financed subsidies from their cantons (states), ensuring that everyone has access to a basic package of services, which include most physician visits, hospital care, pharmaceuticals, devices, and physiotherapy. Additionally, the reform prevents insurers from profiting off of basic coverage, incentivizes competition between the insurers, and allows for the option to purchase supplementary care in order to drive down costs and maintain choice.</p><p>While the 1994 reform bill was a major step in the right direction, it did not address the issue of quality of care. Throughout its history, Switzerland’s hospitals and healthcare workers were paid through a fee-for-service model, which incentivized longer hospital stays to squeeze as much profit out of patients as possible. Thankfully, the Swiss realized that this is neither a sustainable nor just method of delivering healthcare and passed a new reform law in 2007 that changed the payment model to a <a href="https://yaleglobalhealthreview.com/2015/10/03/switzerland-regarding-health-system-reform/#:~:text=In%20an%20effort%20to%20strengthen,through%20a%20regulated%20private%20market.">diagnosis-related group system</a>, which according to the Yale Global Health Review, pays hospitals based on a quality-of-care basis, thus incentivizing higher healthcare quality.</p><p>Even though the Swiss healthcare system is relatively decentralized, the government plays an important role in regulation. According to <a href="https://www.commonwealthfund.org/international-health-policy-center/countries/switzerland">a profile written by the Commonwealth Fund</a>, the federal, cantonal, municipal governments have very distinct responsibilities. The federal government is responsible for overseeing public health initiatives (e.g. response to the COVID-19 pandemic), ensuring safety and quality of devices and pharmaceuticals, and promoting research and training, the cantonal governments coordinate hospital services, licenses healthcare providers, and subsidizes individual premiums, while the municipal governments organize and provide long-term care and social support services for vulnerable groups. As can be seen in the graphic below, the highly decentralized nature of the Swiss healthcare system allows for each institution to carry out its specific responsibilities, thereby maximizing efficiency.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/723/0*USTUUirRBQgwR4CO" /><figcaption>Source: The Commonwealth Fund</figcaption></figure><h4><strong>Why does this system work?</strong></h4><p>In today’s political climate, the terms “universal” and “private” seem contradictory. However, given that Switzerland’s healthcare system ranks tenth in the US News’s ranking of global healthcare systems, it is clear that the Swiss have made a universal, privatized healthcare model work for them.</p><p><a href="https://www.pbs.org/newshour/show/how-switzerland-delivered-health-care-for-all-and-kept-its-private-insurance">Thomas Zeltner, former Swiss Secretary of Health, explains</a> that in the nineties, over seventy percent of the Swiss population believed that everyone should have access to healthcare since it is an “essential part of well-being”. Additionally, the Swiss really like free-market capitalism and the freedom to choose. These two cultural factors played a major role in shaping the Swiss healthcare system and its innovations, one of which was separating health insurance from employment entirely, allowing most citizens to keep their jobs amid the coronavirus pandemic and keeping the unemployment rate from spiking. Additionally, as <a href="https://www.pbs.org/newshour/show/how-switzerland-delivered-health-care-for-all-and-kept-its-private-insurance">William Brangham of PBS reports, </a>there are roughly 60 private companies selling health insurance plans, giving citizens many plans and healthcare providers to choose from. This high level of competition led to lower wait times, higher doctor pay, and as a result, higher quality of care. According to Victor Rodwin, a healthcare policy expert from New York University, these factors all contribute to the Swiss having the lowest avoidable mortality rate (mortality amenable to healthcare intervention).</p><p>Since the government plays a positive role in regulating the Swiss healthcare market, citizens have a high level of trust in their government. An anonymous woman recounted in a PBS interview that even though her husband lost her job and their income dried up due to healthcare expenses, she was still satisfied with the quality of care. It becomes clear that although the government strictly enforces all citizens to get healthcare insurance, everyone is happy to comply since they know the high quality of the product they are getting despite the higher costs.</p><p>In the United States, the terms “universal” and “privatized” appear contradictory. However, Switzerland’s universal, privatized model is clearly working, as it has <a href="https://www.oecd-ilibrary.org/sites/3b4fdbf2-en/index.html?itemId=/content/component/3b4fdbf2-en#:~:text=The%20average%20aged%2Dstandardised%20mortality,and%20Mexico%20(Figure%203.9).">one of the lowest avoidable mortality rates in the world</a>. In order for the United States to address its healthcare system’s many inequities, one first step would be to make health insurance independent of employment. At least <a href="https://www.epi.org/publication/health-insurance-and-the-covid-19-shock/">12 million people have lost their health insurance due to job loss from COVID</a>, and this could be one reform the US should implement. Obviously, both countries’ healthcare systems aren’t perfect, but the Swiss appear to be far happier with theirs than Americans.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=bbd7f6fcc14b" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[COVID-19: Honing in on the Homeless]]></title>
            <link>https://medium.com/@cube.ucla/covid-19-honing-in-on-the-homeless-ec761f6baf83?source=rss-e7d22e79faf3------2</link>
            <guid isPermaLink="false">https://medium.com/p/ec761f6baf83</guid>
            <category><![CDATA[reform]]></category>
            <category><![CDATA[california]]></category>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[homelessness]]></category>
            <dc:creator><![CDATA[CUBE @UCLA]]></dc:creator>
            <pubDate>Fri, 08 Jan 2021 00:28:19 GMT</pubDate>
            <atom:updated>2021-01-08T00:28:19.434Z</atom:updated>
            <content:encoded><![CDATA[<h4>Problems with the U.S. population experiencing homelessness, California’s failures in addressing them, and an overview of steps that should be taken.</h4><h4>By Darren Wijaya</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/1012/0*-FotjWu7luZ6G0nA" /><figcaption>Source: Salud America</figcaption></figure><blockquote>“Freedom is meaningless if people cannot put food in their stomachs, if they can have no shelter, if illiteracy and disease continue to dog them.” — Nelson Mandela</blockquote><p>With the COVID-19 pandemic looming over the world, Mandela’s sentiment becomes all the more accurate as the poverty-stricken scramble in search of a safe haven to avoid contracting an invisible virus. In the United States, populations experiencing homelessness demonstrate how the less-fortunate are coping with a worldwide crisis. Due to lack of access to shelter and sanitary facilities, people experiencing homelessness are particularly vulnerable to COVID-19. This is added with the fact that people experiencing homelessness are more prone to diseases that exacerbate a person’s chances of dying from the disease. With that being said, how are populations experiencing homelessness in the Land of Liberty faring against the pandemic?</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*SdhYxcNneF_CCBy8" /><figcaption>Source: National Alliance to End Homelessness</figcaption></figure><h4><strong>U.S. Population Experiencing Homelessness</strong></h4><p>In 2019, the United States Department of Housing and Urban Development (HUD) reported that 567,715 people experienced homelessness, a marked 3 percent increase from the previous year. Over 37 percent of the overall population is unsheltered, residing in locations that are considered uninhabitable and can cause critical health conditions. This number is especially important since sheltering and constant sanitizing are considered very effective preventative measures against COVID-19, so people who lack access are at a very high risk of catching the virus. This is further aggravated by the fact that people experiencing homelessness are much more prone to respiratory diseases, such as asthma and pneumonia, as well as autoimmune diseases which heavily increase a person’s chances of succumbing to COVID-19. However, reports of COVID-19 related deaths in populations experiencing homelessness are brushed aside by the HUD, with no real data of the death toll ever being recorded. Without knowing the number of deaths in the population, the impact of COVID-19 on populations experiencing homelessness could be much worse than what is portrayed in media coverage.</p><h4><strong>California’s Project Roomkey: A Case of Mismatch</strong></h4><p>As the nation’s leader in the number of people experiencing homelessness, California’s COVID-19 condition is a cause for concern. In early 2019, over 150,000 people were experiencing homelessness in California, accounting for almost 27% of the entire U.S. population experiencing homelessness. With a very large vulnerable population, California’s government has decided to allocate a $150 million budget on a program called “Project Roomkey” which aimed to rent 15,000 hotel rooms statewide to place the shelterless in safer and cleaner havens. On paper, the idea seemed stunning as it could help alleviate the homelessness crisis as well as prevent the further spread of the virus in vulnerable populations. However, the outcome was different. In LA County, the goal was to rent 15,000 rooms but after 4 months, less than 30% of the goal was fulfilled. This was due to a number of reasons. Firstly, numerous hotels closed their doors to the project as the managers felt that placing the homeless in their rooms would tarnish their brand image and thus lower sales. Secondly, some hotels claimed that their rooms were already occupied with different essential workers especially in the healthcare field, and could not provide more rooms for the project. Finally, since the project required that people experiencing homelessness be placed in their rooms for an indefinite amount of time without exit, many people were reluctant to be placed in these rooms and preferred to live in more crowded tent spaces and outdoor shelters that allowed more freedom albeit more exposure to the virus. Due to this reluctance, many rooms that were already rented remained unoccupied for long periods of time, which meant that government funding was being poured down the drain for this ineffective project.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*M6auu5KPuFKRoGfl" /><figcaption>Source: Los Angeles Daily News</figcaption></figure><h4><strong>Tent to Tent</strong></h4><p>Another initiative that the Californian government utilized was to provide people experiencing homelessness with tents that were provided by nonprofit organizations. This initiative allowed these people to place their tents in the most desired areas, which already spelled disaster. Many of these people placed their tents in crowded areas that were close to business districts. Because these people were not asked to remain stationary in their tents, they wandered around their tents near workplaces, which endangered both the people experiencing homelessness as well as people living or working in the vicinity. The condition of the area became very poor to an extent that many businesses, including the University of California’s Hastings College of Law, filed lawsuits against the Californian government for the initiative. In summation, California’s handling of the homelessness crisis in the current pandemic era has not been very effective.</p><h4><strong>Notes on Improvement: England’s Everyone In and California’s Hepatitis A Epidemic</strong></h4><p>In order to improve, both California and the United States as a whole could look to other countries and their successes in handling the situation. England, for instance, had a program called “Everyone In” where its population experiencing homelessness was placed not only in vacant hotel rooms but also in places that were emptied due to the pandemic, such as student dormitories and temporary housing locations that are much less expensive than hotel rooms. The government treats the program as a temporary initiative and has started to arrange an “exit plan” where homes are being built in order to move these people into more permanent housing locations. The program has seen many successes, with over 15,000 people already being moved into these temporary spots, with some even obtaining employment. In addition to “Everyone In,” England has also implemented “COVID-CARE”, where people experiencing homelessness that show symptoms of COVID-19 are provided testing and medical accommodations for those who test positive, which ensure that COVID-19 cases in the population experiencing homelessness remain controlled.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*MOflEndte4ps9Buq" /><figcaption>Source: Shelter Blog</figcaption></figure><p>Aside from England, California could also review its past examples of how it handled disease outbreaks in populations experiencing homelessness. In 2017, San Diego experienced a Hepatitis A outbreak that disproportionately affected people experiencing homelessness. In order to minimize the deaths, San Diego County teamed up with healthcare providers in order to prevent the outbreak from spreading further. This included rapid installations of new testing sites and sanitation facilities and increasing education in volunteers regarding vaccine installation, proper use of hygiene and health kits, and coordinating with populations experiencing homelessness. People experiencing homelessness were then educated on practicing hygiene, protocols on how and where to receive vaccinations and treatment, and on the Hepatitis A disease overall. Due to the rapid response, deaths were kept to a minimum and the outbreak was quickly resolved.</p><p>The examples above highlight that there are still many things lacking in California’s response. Primarily, it needs to invest in more permanent housing for populations experiencing homelessness that has the potential to reduce government spending and improve the population’s condition in the long run. In addition, the government also needs to implement a more robust testing system to keep COVID-19 cases low in the population. Since government budgets are limited, external sources could prove useful in tackling this problem. For instance, nonprofit organizations such as Habitat for Humanity could help in building homes, and biotechnology and healthcare companies could provide the government with the tools and medical devices necessary that can make testing and treatment for the population more affordable and thus more widespread. Volunteers should also be increasingly employed and educated in order to handle increasing tasks and to communicate with people experiencing homelessness better in order to avoid more mismatches. Although vaccines are still in development, the government needs to prepare for when the vaccines become ready to ensure that vulnerable populations such as populations experiencing homelessness can obtain easy access to these vaccines in the future. These improvements are not inexpensive but we must not disregard the dreadful conditions of people experiencing homelessness either.</p><p>Due to the pandemic, unemployment levels are rising which means that the number of people experiencing homelessness will increase as well. The U.S. government needs to act fast in combating the issue in order to halt the problem from exacerbating even further.</p><h4>References:</h4><ul><li><a href="https://endhomelessness.org/homelessness-in-america/homelessness-statistics/state-of-homelessness-2020/">State of Homelessness: 2020 Edition - National Alliance to End Homelessness</a></li><li><a href="https://www.usatoday.com/story/news/investigations/2020/08/28/covid-19-invisible-victims-homeless-people/5636938002/">COVID-19: The &#39;crisis within a crisis&#39; for homeless people</a></li><li><a href="https://knock-la.com/homeless-los-angeles-project-roomkey-lahsa-12027aafec7b">Project Roomkey is Failing in Los Angeles — Now We Know Why</a></li><li><a href="https://www.sfchronicle.com/bayarea/article/Lawsuit-San-Francisco-needs-to-clean-up-the-15245770.php#photo-19374422">&#39;Lives are in danger&#39;: Lawsuit argues SF needs to clean up the Tenderloin as coronavirus spreads</a></li><li><a href="https://www.theatlantic.com/international/archive/2020/07/what-coronavirus-proved-about-homelessness/614266/">What the Coronavirus Proved About Homelessness</a></li><li><a href="https://cloudburstgroup.com/helping-homeless-epidemic/">Helping the Homeless During an Epidemic</a></li></ul><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=ec761f6baf83" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Why Healthcare Continues to Cost the Land of The Free a Pretty Penny]]></title>
            <link>https://medium.com/@cube.ucla/why-healthcare-continues-to-cost-the-land-of-the-free-a-pretty-penny-347e7c9833d6?source=rss-e7d22e79faf3------2</link>
            <guid isPermaLink="false">https://medium.com/p/347e7c9833d6</guid>
            <category><![CDATA[inequality]]></category>
            <category><![CDATA[healthcare-system]]></category>
            <category><![CDATA[health-insurance]]></category>
            <category><![CDATA[usa]]></category>
            <category><![CDATA[international]]></category>
            <dc:creator><![CDATA[CUBE @UCLA]]></dc:creator>
            <pubDate>Sat, 30 May 2020 09:37:55 GMT</pubDate>
            <atom:updated>2020-06-17T16:28:02.049Z</atom:updated>
            <content:encoded><![CDATA[<h4>US Healthcare Expenditure, a Comparison with other Countries and Healthcare System Structures.</h4><p>By Rei Tan</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*WXQiFlToouGsPSlB709MdQ.png" /><figcaption>Source: Healthcare Global</figcaption></figure><p>The healthcare system in the United States is far from simple to understand. The majority of its complexity is owed to the heterogeneity of financing sources. Unlike many other countries, <strong>the US lacks a single-payer system when it comes to health care policies such as insurance</strong>. This multi-payer framework, combined with the comparative lack of cost control for health care procedures and services, contributes significantly to the astonishing difference in healthcare costs between the US and the rest of the world.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/960/1*s-JKgJwra18UVDMhQDEdEw.jpeg" /><figcaption><a href="https://www.forbes.com/sites/niallmccarthy/2019/08/08/how-us-healthcare-spending-per-capita-compares-with-other-countries-infographic/#52510b12575d">Per capita health expenditure in selected countries in 2018</a>. Forbes</figcaption></figure><h3>US Healthcare Expenditure</h3><p>As of 2018, the US spent a whopping 16.9% of its GDP on healthcare according to the statistics provided by OECD. The US tops the list for healthcare expenditure among OECD countries with these figures. Yet, it seems that despite the heavy spending on healthcare, Americans benefit from a relatively less robust healthcare infrastructure than citizens of other countries. Healthcare data from OECD Healthcare Statistics in 2015 reported the number of practicing physicians in the US as 19% lower than the OECD median. Similarly, the population of practicing nurses in the US was 20% below the OECD median. To add insult to injury, the US had far fewer hospital beds dedicated to inpatient acute care, and Americans had a shorter average length of hospital stay.</p><ul><li><a href="https://stats.oecd.org/Index.aspx?DataSetCode=SHA">Health expenditure and financing</a></li><li><a href="https://jhu.pure.elsevier.com/en/publications/its-still-the-prices-stupid-why-the-us-spends-so-much-on-health-c">It&#39;s still the prices, stupid: Why the US spends so much on health care, and a tribute to UWE Reinhardt</a></li></ul><h4>Healthcare Expenditure and Consumption Mismatch</h4><p>So what factors account for such a mismatch between healthcare expenditure and consumption? Ironically, one of the key contributors is the policy that, in most cases, is meant to abate high costs and protect its ward. Most of health care coverage in the United States is provided by employers, while other forms of coverage can come in the forms of public or private insurance. However, there exists no form of a national system of insurance policy with regards to health. The absence of such a universal policy increases the vulnerability of US citizens, and the existing policies that are financed by public sources cover a much smaller proportion of the national population than other countries.</p><p>Problems arise from the variances in coverage provided by different plans. Less than 30% of the US employee population is provided with a plan that allows for an unrestricted choice of provider and a conventional fee-for-service reimbursement system. The majority of employer-provided insurance schemes are affiliated with Health Maintenance Organisations (HMOs) and Preferred Provider Organisations (PPOs). These drastically restrict consumer choice in their healthcare provider. An employee with insurance coverage provided under these selective contracting policies will have to bear a considerable portion or full financial cost if they were to choose outside of these networks. Meanwhile, under public programs such as Medicare or Medicaid, physicians can choose to accept or reject assignments. Accepting assignments would mean that a physician cannot charge outside a federally-approved fee while rejecting assignments would open up the opportunity for the physician to charge a higher price, and patients will only receive 80% of the Medicare fee as reimbursement. This incurs a good deal of the cost on a patient that might not be able to afford the additional costs out-of-pocket. The issue becomes much more sinister when we realize that this lack of transparency in price allocation and determination of costs can cause debts incurred by insurance and healthcare service providers to be ultimately borne by the consumer<a href="#_edn5">[v]</a>.</p><ul><li><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633404/">Comparisons of Health Care Systems in the United States, Germany and Canada</a></li><li><a href="https://international.commonwealthfund.org/countries/japan/">International Health Care System Profiles</a></li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/708/1*Z-vZGpmvPUZoDFEahwS6BA.png" /><figcaption>Sources of financing in the American healthcare system (Fig 2.3, <a href="https://link.springer.com/chapter/10.1007%2F978-3-662-59568-8_2">Main Characteristics of the American Healthcare System</a>)</figcaption></figure><h3>Healthcare System Structure</h3><p>The high premiums coupled with out-of-pocket costs are enough to hurt patients substantially, but the problem did not start, nor does it end with insurance policies. Insurance premiums often reflect the actual cost of healthcare provision. Failure to control the costs of services in the sector holds just as much liability to the unabated rising cost of healthcare. The US enjoys great access to advanced medical technology which is often expensive. It also suffers from pervasive malpractice concerns held by physicians. As a result, physicians in the United States frequently practice “defensive medicine”, incurring great cost through supplementary tests and procedures.</p><p><a href="https://www.aeaweb.org/articles?id=10.1257/jep.22.4.27">Is American Health Care Uniquely Inefficient?</a></p><p>We need not look too far to find differences in effective cost-reduction policies. While the United States has close to no policies implemented to control cost, its neighbor to the north has put into effect strategies to bring healthcare expenditure down. In addition to prohibiting any overlap of private health insurance with public coverage policies, Canada has limited high-tech services and distributed its supply of such equipment to reduce costs incurred by expensive diagnostic procedures and equipment such as CT scans. Germany has undertaken similar regulation and limitation of capital equipment, and the freedom of choice concerning healthcare providers resulting in supply-side competition has supplemented the reduction in cost.</p><blockquote>Both countries also feature a nationwide insurance scheme which aids in providing ample subsidisation of healthcare costs for consumers. Perhaps unsurprisingly, physicians in Canada and Germany have drastically lower salaries than those in the United States.</blockquote><blockquote>If we look a little farther to the East, we might find it interesting to note that Japan has not compromised in their provision of advanced technological procedures. Japan ranks lowest in terms of overall expenditure among the OECD and has accomplished this through stringent price controls as well as payment revisions, emphasis on efficient pharmaceutical utilisation and development of alternative care strategies.</blockquote><p><a href="https://international.commonwealthfund.org/countries/japan/">International Health Care System Profiles</a></p><p>While these are by no means the only two factors that contribute to the United States’ substantial healthcare expenditure figures, they are possibly the most apparent and palpable. Likewise, this article is far from an exhaustive analysis of contributing elements to the exorbitant amount spent on healthcare in the US. The United States’ healthcare system is immensely complex and also flawed, but it is also responsible for great innovation in the realm of drugs, pharmaceuticals, and medical technology It would be an oversight to ignore the benefits that come from heavy investment in these sectors made possible through healthcare expenditure. The issue of reducing healthcare costs is a tricky one, but we must not shy away from the challenge.</p><p>To turn a blind eye to the shortcomings of our healthcare system would be to guarantee a handicap in our future development. Indeed, solving some of the ailments of the system may heal or even protect against complications in areas and sectors of society outside of health.</p><p><em>Rei Tan is a Neuroscience, Study of Religion double major at UCLA from Singapore. Rei believes that policy and healthcare administration is just as important to the healthcare sector as medicine. This topic can answer questions like why someone might or might not receive medical treatment even though it is available. It might also be able to answer the question of why the world is suffering in different degrees in situations such as the current pandemic.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=347e7c9833d6" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Essential Workers take care of us, but do we take care of them?]]></title>
            <link>https://medium.com/@cube.ucla/essential-workers-take-care-of-us-but-do-we-take-care-of-them-7a2b4fcde6cb?source=rss-e7d22e79faf3------2</link>
            <guid isPermaLink="false">https://medium.com/p/7a2b4fcde6cb</guid>
            <category><![CDATA[covid-19-crisis]]></category>
            <category><![CDATA[cdc]]></category>
            <category><![CDATA[amazon]]></category>
            <category><![CDATA[osha]]></category>
            <category><![CDATA[essential-worker]]></category>
            <dc:creator><![CDATA[CUBE @UCLA]]></dc:creator>
            <pubDate>Mon, 25 May 2020 06:57:18 GMT</pubDate>
            <atom:updated>2020-05-25T06:57:18.951Z</atom:updated>
            <content:encoded><![CDATA[<h4>Defining Essential Workers, OSHA &amp; CDC’s Efforts, and the Amazon Problem.</h4><p>By Havish Gattu</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*D3ljZPE43Et-OaLXAYMmHg.png" /><figcaption>Source: The Guardian</figcaption></figure><h3>Who are Essential Workers?</h3><p>In the wake of the terrifying COVID-19 pandemic, communities all over the United States have come together with a fabulous display of unity as they praise the heroic work of our essential workers. A great example of our country’s support was when New Yorkers had organized a massive citywide clap with the help of the hashtag “#ClapBecauseWeCareNYC” on twitter. But while we may clap for many of the doctors, nurses, and first responders risking their lives day by day, how far has this appreciation reached for the <em>other</em> essential workers that have been pleading for our help? What the public tends to forget is that the category of essential workers includes a variety of people that we depend on to keep our economy running, to bring food to our doorsteps, and to take care of our loved ones.</p><h3>NYC Mayor&#39;s Office on Twitter</h3><p>At 7 pm we clap for our heroes. We clap for every medical professional in New York City. We clap for the hometown heroes on the front lines. We clap for the people from around the country who traveled here to help save lives. We #ClapBecauseWeCare. https://t.co/qXtrGPkiZL</p><p>Regardless of the sacrifices they make, <em>employees of manufacturing and retail companies</em> have been immensely sidelined in the effort to support our essential workers, especially by OSHA and CDC regulations.</p><h3>Steps by OSHA and CDC</h3><p>Naturally, the question on everyone’s mind: what exactly is the stance that OSHA and the CDC have taken?</p><p>You can find this stance <a href="https://www.osha.gov/Publications/OSHA3990.pdf">here</a>. The publication states the following</p><blockquote>Employers must provide their employees with a workplace free from recognized hazards likely to cause death or serious physical harm.</blockquote><p>This sounds nice and dandy, but is barely impactful because the first sentence of this article — and I mean the FIRST — is that this is not a standard or regulation and creates “<strong>no legal obligations</strong>.” If OSHA cannot put its foot down and set hard regulations to ensure workers aren’t exploited during this terrifying pandemic, what incentive do companies have to compromise on maximizing their profits at the expense of worker safety? Wasn’t OSHA’s main purpose to REGULATE companies from doing exactly that? How is putting up a voluntary recommendation safeguarding anyone’s right to safety?</p><p>Let’s just say we were to believe in the kindhearted nature of multinational corporations and allow the lives of millions of our cherished heroes to depend on this belief. After all, these companies MUST care about their employees. Then why would records obtained in a freedom of information act request form directed at OSHA find that <strong>almost 4,000 workers across the country have expressed concern to federal agencies that their employers aren’t doing enough to protect them from COVID-19?</strong></p><p><a href="https://www.propublica.org/article/millions-of-essential-workers-are-being-left-out-of-covid-19-workplace-safety-protections-thanks-to-osha">Millions of Essential Workers Are Being Left Out of COVID-19 Workplace Safety Protections, Thanks to OSHA</a></p><p>What was OSHA’s response after hearing these complaints? They eliminated non-healthcare workers from government protection. Both OSHA and the CDC weakened protections for any non-medical field related essential workers. OSHA stated that it would not formally handle any complaints about coronavirus from non-medical personnel.</p><p>When asked about the immorality of providing regulation for only a few, OSHA responded by stating that they simply did not have the personnel to do spot-checks and enforce any regulations set forth. Is that enough reason to not set forth any legal regulation? Let’s look at the case of other pandemics that OSHA has dealt with in the past. The response to the H1N1 virus was strong, with OSHA testifying that the agency will “use the ‘General Duty Clause’ of the Occupational Safety and Health Act,” which <strong>requires</strong> employers to provide hazard-free work zones. They stated that they would “aggressively enforce safe work practices.”</p><p><a href="https://www.osha.gov/news/testimonies/05072009">Ensuring Preparedness Against the (H1N1) Flu Virus at School and Work | Occupational Safety and Health Administration</a></p><p>Just the verbose of this testimony holds companies to a much higher standard than what is being held during the current pandemic. OSHA’s response to Ebola held the same strong message. Once again, the federal body <strong>required</strong> employers to protect workers, even going far enough to require employers to “implement infection prevention and control measures” once again using the ‘General Duty Clause.’</p><p><a href="https://www.osha.gov/SLTC/ebola/standards.html">Safety and Health Topics | Ebola - Standards | Occupational Safety and Health Administration</a></p><p>Both H1N1 and Ebola were terrifying and tragic but have not affected our community to the scale that COVID-19 has. While the General Duty Clause was mentioned in the COVID-19 publication, the constant reminder that the article only provides recommendations that are advisory completely dispels the severity of the pandemic. Why has the response been so diluted when this pandemic is so comparatively severe?</p><h3>Focusing on the Amazon Issue</h3><p>In order to see the real effects of the relaxed nature that OSHA’s stance, we must look at some first-hand accounts from the infamously stringent Amazon corporation. The company has already been known to have a fractious relationship with its employees, with many accounts describing the company’s priority of efficiency as being mentally and physically destructive.</p><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fwww.youtube.com%2Fembed%2FKRvorrGmYfY%3Ffeature%3Doembed&amp;display_name=YouTube&amp;url=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DKRvorrGmYfY&amp;image=https%3A%2F%2Fi.ytimg.com%2Fvi%2FKRvorrGmYfY%2Fhqdefault.jpg&amp;key=a19fcc184b9711e1b4764040d3dc5c07&amp;type=text%2Fhtml&amp;schema=youtube" width="854" height="480" frameborder="0" scrolling="no"><a href="https://medium.com/media/25d6f25d35308f0e149b70b54c522efb/href">https://medium.com/media/25d6f25d35308f0e149b70b54c522efb/href</a></iframe><p>The video above provides an account from amazon workers who had the courage to come out and explain the true lack of care that employees must face from their employers. Now, with the pandemic spreading through the nation, the employees could be in even more danger. They work shoulder to shoulder as the asymptomatic virus makes its way through them one by one. Walkouts have been staged, one occurring due to a warehouse worker named Chris Smalls. He was only able to rally 50 workers who were not afraid of their corporate bosses. Chris Smalls was fired the same day for violating a quarantine. Smalls says he was never warned while Amazon disputes saying he was told to stay home with pay to decrease risk since Smalls was exposed to a co-worker who had corona.</p><p><a href="https://www.washingtonpost.com/technology/2020/03/30/worker-strike-instacart-amazon-whole-foods/">Workers protest at Instacart, Amazon and Whole Foods for health protections and hazard pay</a></p><p>If we genuinely care about the safety of our fellow community members, and the safety of our own family, we must bring attention to this issue. Keep in mind, that these lax regulations put both the worker’s and your lives in danger. Every amazon delivery that makes its way to houses throughout the nation comes from a warehouse where employees are overworked to exhaustion. Every delivery comes from warehouses where correct safety standards are not upheld putting your family at risk from contracting the disease. Ensuring the safety of every individual in our community will ensure the safety of our families, and of consequently, our nation.</p><p><a href="https://www.wsj.com/articles/amazon-struggles-to-find-its-coronavirus-footing-its-a-time-of-great-stress-11585664987?mod=hp_lead_pos5">Amazon Struggles to Find Its Coronavirus Footing. &#39;It&#39;s a Time of Great Stress.&#39;</a></p><p><em>Havish Gattu is a pre-med and Biology major at UCLA from Frisco, with a passion for dance, literature, and philosophy. Havish is interested in understanding how legal systems allow for the many injustices present in our healthcare system and focuses on how businesses and the government are mistreating essential workers during the COVID-19 pandemic.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7a2b4fcde6cb" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Disposable biopharmaceutical manufacturing plants: Technology of the future?]]></title>
            <link>https://medium.com/@cube.ucla/disposable-biopharmaceutical-manufacturing-plants-technology-of-the-future-d02857276e9f?source=rss-e7d22e79faf3------2</link>
            <guid isPermaLink="false">https://medium.com/p/d02857276e9f</guid>
            <category><![CDATA[pharmaceuticals-industry]]></category>
            <category><![CDATA[healthcare-technology]]></category>
            <category><![CDATA[drug-manufacturing]]></category>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[manufacturing]]></category>
            <dc:creator><![CDATA[CUBE @UCLA]]></dc:creator>
            <pubDate>Mon, 25 May 2020 06:45:59 GMT</pubDate>
            <atom:updated>2020-05-25T06:45:59.314Z</atom:updated>
            <content:encoded><![CDATA[<h4>Single-use bioprocessing and it’s benefits, limits and future scope</h4><p>By Pooja Bhatnagar</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*30IlIe6mmoyIsZMU.jpg" /><figcaption><strong>Figure 1</strong>: Single-use bioreactor (Source: <a href="https://www.genengnews.com/magazine/328/supplement-automating-the-adoption-of-single-use-technology/">www.genengnews.com</a>)</figcaption></figure><h3><strong>Introduction</strong></h3><p>The process of manufacturing biopharmaceutical medicines is extremely complicated, at best. Take a moment to imagine what a biologics manufacturing plant looks like.</p><p>Picture a large, sterile facility filled with many rows of enormous stainless steel bioreactor tanks bolted to the floor, connected to an intricate system of steel pipes snaking around them, and countless complicated measurement gadgets connected to those pipes and reactors.</p><p>It would probably look similar to the facility depicted below:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/800/0*dZXUT9MNGQuV-AbM" /><figcaption><strong>Figure 2</strong>: Traditional bioprocessing plant (Source: <a href="https://www.wsj.com/articles/samsungs-bet-on-biotechnology-is-test-for-heir-apparent-1450386875">www.wsj.com</a>)</figcaption></figure><p>Depending on the size of the facility, each of those stainless steel bioreactors can hold from 100L to a whopping 20,000L of material at once for bioprocessing, which simply put, is any process that uses biological components to obtain the desired product.</p><p><a href="https://www.pharma-iq.com/glossary/bioprocessing">Pharma IQ</a></p><p>Usually, a facility like this would take up to two to three years to get up and running, costing $200 to $500 million to build. These facilities, due to the virtue of large reactors, are usually used for manufacturing drugs and biologics at the commercial scale.</p><p><a href="https://bioprocessintl.com/manufacturing/facility-design-engineering/construction-and-start-up-costs-for-biomanufacturing-plants-182238/">Construction and Start-Up Costs for Biomanufacturing Plants - BioProcess International</a></p><p>However, when it comes to manufacturing on a smaller scale, such as for clinical trials, local production, or small niche markets, these traditional facilities make less sense.</p><p>In an effort to reduce the time required for initiation and the cost required to run manufacturing processes, a more flexible and cost-effective option has been introduced known as single-use bioprocessing, or disposable bioprocessing. Within the last decade, disposable equipment has actually been a critical disruptive technology in the successful, cost-effective manufacturing of many biologics.</p><ul><li><a href="https://bioprocessintl.com/manufacturing/facility-design-engineering/efficient-flexible-facilities-for-the-21st-century-337813/">Efficient, Flexible Facilities for the 21st Century - BioProcess International</a></li><li><a href="https://www.americanpharmaceuticalreview.com/Featured-Articles/190920-The-Benefi-ts-and-Limits-of-Disposable-Technologies-In-Manufacturing-Protein-Therapeutics/">The Benefits and Limits of Disposable Technologies In Manufacturing Protein Therapeutic</a></li></ul><h3><strong>What does single-use bioprocessing look like?</strong></h3><p>Single-use systems include bioprocessing equipment that is used once and then discarded. It includes single-use ‘reactors’, which are essentially disposable but high-quality plastic bags that are held in a portable, stainless steel system designed to hold bags of the desired volume. In addition, all media and buffers are also prepared in single-use bag systems with internal disposable mixing systems, weighing station and disposable plastic tubings, filters, etc for moving the contents into and out of the bags. The piping and other equipment are generally sealed and sterilized with gamma rays to make them suitable for drug manufacturing.</p><ul><li><a href="https://bioprocessintl.com/upstream-processing/upstream-single-use-technologies/single-use-technology-and-modular-construction-341774/">Single-Use Technology and Modular Construction - BioProcess International</a></li><li><a href="https://www.pharmamanufacturing.com/articles/2016/investment-in-biopharma-facilities-continues/">Investment in Biopharma Facilities Continues</a></li></ul><p>(<strong>Note</strong>: The term single-use or disposable bioprocessing can be misleading at first glance — it is important to note that only the plastic bags and other plastic components are single-use, whereas the stainless steel tanks that hold those bags are retained.)</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/600/0*MmzvRlFZaQhJc027" /><figcaption><strong>Figure 3</strong>: Single-use bioprocessing plant (Source: <a href="https://bioprocessintl.com/manufacturing/facility-design-engineering/construction-and-start-up-costs-for-biomanufacturing-plants-182238/">bioprocessintl.com</a>)</figcaption></figure><p>Currently, the largest bioreactors with capacity for single-use components have a capacity for 3,500L of material, which is much smaller than the traditional maximum of 20,000L. This restriction is due mostly due to the fact that the amount of reactant that can be used depends on how much pressure a reactor can handle.</p><p><a href="https://www.americanpharmaceuticalreview.com/Featured-Articles/354820-Biopharmaceutical-Manufacturing-is-Shifting-to-Single-Use-Systems-Are-the-Dinosaurs-the-Large-Stainless-Steel-Facilities-Becoming-Extinct/">Biopharmaceutical Manufacturing is Shifting to Single-Use Systems. Are the Dinosaurs, the Large Stainless Steel Facilities, Becoming Extinct?</a></p><p>It would make sense that plastic components cannot withstand what fully stainless steel components can, so single-use equipment cannot practically be as large.</p><p>Although single-use bioprocessing units are constrained in size, there has been a significant increase in manufacturing productivity in the biopharmaceutical industry over the past decade, leading to higher titers (reaction yields). This means that even with the smaller single-use containers, larger amounts of the drug can be manufactured, even to the commercial-scale. As of now, most commercial manufacturing still uses traditional bioprocessing equipment, but it is set to rely increasingly on disposables in the foreseeable future.</p><p><a href="https://www.wsj.com/articles/samsungs-bet-on-biotechnology-is-test-for-heir-apparent-1450386875">Samsung&#39;s Bet on Biotechnology Is Test for Heir Apparent</a></p><h3><strong>Benefits of single-use bioprocessing</strong></h3><h4>Significant time savings</h4><p>There are two distinct areas of significant time savings using the single-use bioprocessing — shorter time for construction of the facility, and recurring time savings between individual batches of drug production.</p><p>It takes approximately one year for a single-use bioprocessing plant to go from an empty facility to a fully-ready-to-manufacture facility. Since traditional facilities typically take two to three years before they are fully ready, using this newer technology saves one to two years for manufacturing and distributing, and thus one to two years of extra revenue and a return on investment 25% faster.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/19623478/">Hybrid and Disposable Facilities for Manufacturing of Biopharmaceuticals: Pros and Cons - PubMed</a></p><p>One to two years of extra revenue may not seem to be that much in the big picture, but considering that highly successful drugs like Amgen, Inc.’s Enbrel have brought in $5 billion in one year, that extra time could mean millions to billions of more dollars for a pharmaceutical company if the drug is successful.</p><p>The American Pharmaceutical Review says that</p><blockquote>“With [single-use] equipment essentially plug-and-play, process turnaround and set up of new processing lines are much quicker, avoiding weeks of cleaning / sterilization / validation required with reused stainless steel equipment.”</blockquote><p>The shift time between batches of different products is up to five times faster when dealing with single-use bioprocessing than with traditional methods, which is a huge time-saver.</p><p><a href="https://www.europeanpharmaceuticalreview.com/article/85348/single-use-bioprocessing/">Paving the way to a bright future for single-use bioprocessing</a></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/500/0*pXIIZGcpL0UrGX4u.jpg" /><figcaption><strong>Figure 4</strong>: Single-use bioreactor (Source: <a href="https://www.genengnews.com/magazine/288/markets-expand-for-single-use-bioreactors/">www.genengnews.com</a>)</figcaption></figure><h4>Less risk of cross-contamination between runs</h4><p>A huge advantage of disposable technology is the lower cross-contamination risks with the use of new bags for each run since the disposable equipment comes already sterilized from suppliers. This means that there are fewer sterility validation issues due to the absence of cleaning requirements, saving even more time.</p><p>So when it comes to expansion, process switching or improvement, or changes in the equipment or products, single-use disposable equipment yields superior results.</p><h4>Lower costs and greater efficiency</h4><p>Perhaps the most important benefit of single-use bioprocessing equipment is that it requires a lower capital investment and less in maintenance costs, which outweigh the recurring costs of purchasing disposable equipment, which is much cheaper.</p><blockquote>“When compared to traditional stainless-steel equipment, single-use technologies have been shown to reduce capital costs by 40 to 50 percent and operating costs by 20 to 30 percent.”</blockquote><p><a href="https://www.pharmamanufacturing.com/articles/2016/investment-in-biopharma-facilities-continues/">Investment in Biopharma Facilities Continues</a></p><p>We know that traditional bioprocessing facilities take $200 to $500 million to build. Based upon the statistics above and assuming a simple 1:1 capital to operating costs ratio, single-use facilities should save at least $120 million for pharmaceutical companies.</p><p>Since it is effective and cost-saving, disposable bioprocessing equipment is now being used for more than 85 percent of pre-commercial manufacturing and is increasingly used for commercial manufacturing more recently.</p><blockquote>“In many respects, single-use will soon dominate much of biopharmaceutical manufacture, particularly at other than large scales.”</blockquote><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*OJgnJ-WP4Mxi598Q" /><figcaption><strong>Figure 5</strong>: Photo by <a href="https://unsplash.com/@igorson?utm_source=medium&amp;utm_medium=referral">Igor Son</a> on <a href="https://unsplash.com/?utm_source=medium&amp;utm_medium=referral">Unsplash</a></figcaption></figure><h4>More environmentally friendly</h4><p>Although it may, upon first glance, appear that single-use bioprocessing would be less environmentally friendly than traditional bioprocessing — after all, reactor components are switched out after every reaction — the truth is that they actually reduce the environmental footprint of manufacturing facilities in the long run.</p><blockquote>“Very rigorous comparative analyses indicate that single-use bioprocess technologies exhibit lower environmental impact… from terrestrial eco-toxicity to marine eutrophication to ozone depletion.”</blockquote><p>More specifically, a single-use bioprocessing facility uses about 50 percent less energy than a traditional facility due to the heating of water used to clean stainless steel in the latter. Disposables also offer an 85 percent reduction in water usage.</p><p>Although there is room for improvement in terms of the plastic that must be used for single-use processes, it is a far superior choice environmentally than traditional bioprocessing equipment.</p><p><a href="https://bioprocessintl.com/2014/single-use-and-sustainability-351059/">Single-Use and Sustainability - BioProcess International</a></p><h3><strong>Limits of single-use bioprocessing</strong></h3><p>Almost every technology comes with some limitations or downsides. The success of a technology depends greatly on how much the benefits outweigh the limitations, and how easily the downsides can be managed or mitigated.</p><h4>Cost pressure and supplier dependency</h4><p>Since single-use bioprocessing, unlike traditional methods, depends on repetitive purchases of equipment from suppliers, there is a huge dependency on quality suppliers.</p><p>Since there are less than numerous suppliers of disposable bioprocessing equipment in the market, and not every supplier’s stock will be compatible with the stainless steel equipment of a manufacturer, pharmaceutical companies can find themselves dependent upon one supplier.</p><p>The large supply orders necessary for continuous manufacturing, long delivery times, and dependence on equipment quality and sterility assurances from suppliers arise as weaknesses to this method of manufacture. This dependence could also mean lost bargaining power for equipment and therefore higher than necessary costs.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/396/0*eNSGn1vWaW2E7PbZ.png" /><figcaption><strong>Figure 6</strong>: Single-use bioreactor (Source: <a href="https://cellculturedish.com/cool-tool-shape-matters-an-innovative-design-for-single-use-bioreactors/">cellculturedish.com</a>)</figcaption></figure><h4>More time spent on logistics</h4><p>With the use of single-use bioreactors, there are more moving parts to the operation than there would normally be.</p><p>Therefore, there must always remain a careful balance between inventory, consumption, and delivery in order to ensure continuous production. Disposables supplier audits and qualifications must be contended with, and possible leachable and extractable plastic must be tested before every reaction.</p><p>Additionally, the lack of piping in facilities means that the transportation of materials before, during, and after the manufacturing process must be done in mobile containers, requiring more careful tracking. The American Pharmaceutical Review says on this that</p><blockquote>“It is not value generating work which might additionally create a new source of errors by connecting the wrong materials and could be a safety challenge… [and this all] puts more pressure on logistics.”</blockquote><p><a href="https://www.americanpharmaceuticalreview.com/Featured-Articles/190920-The-Benefi-ts-and-Limits-of-Disposable-Technologies-In-Manufacturing-Protein-Therapeutics/">The Benefits and Limits of Disposable Technologies In Manufacturing Protein Therapeutic</a></p><h3><strong>Conclusion</strong></h3><p>Single-use bioprocessing is the technology of the future as we move towards a more eco-friendly and cost-efficient biologics manufacturing industry.</p><p>Far from extreme, this switch is more about shifting the costs and use of space to different areas, yielding significant benefits. PharmTech notes</p><blockquote>“Expensive classified cleanroom spaces can be reduced, but inexpensive storage space is increased; there is an increased cost for consumables, but reduced turnaround time between batches; and there is an overall increase in production time compared to the labor expended.”</blockquote><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*XtwUq2fixgPhzHVy.jpg" /><figcaption><strong>Figure 7</strong> (Source: <a href="https://online.husson.edu/cool-innovations-biotechnology/">online.husson.edu</a>)</figcaption></figure><p>As more and more biopharmaceutical companies discover the benefits of and gain experience mitigating the limitations of disposables in manufacturing, we will see further innovation and operational efficiencies aimed at incorporating it more effectively.</p><p>Large pharmaceutical and biotechnology giants like Amgen, Inc., and Shire Plc (now a part of Takeda Pharmaceutical Company) are paving the way as pioneers of single-use bioprocessing in manufacturing facilities.</p><p>As this industry grows, as it has been for the past decade, it is not absurd that we would begin to imagine biologics manufacturing instead as small facilities with a few stainless steel tanks holding plastic bags in them, disposable bag systems and pipes moving materials around the room, able to produce drugs at commercial scales.</p><p><em>Pooja Bhatnagar is a Human Biology and Society major at UCLA. Pooja is interested in business healthcare and its intricacies in solving meaningful problems. She believes that healthcare has so many opportunities to do so, ranging from industry drug development to healthcare consulting. Apart from academics, Pooja loves to ski, run, and play the piano or the guitar.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d02857276e9f" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[COVID-19 and the Worldwide Hunt for a Vaccine]]></title>
            <link>https://medium.com/@cube.ucla/covid-19-and-the-worldwide-hunt-for-a-vaccine-c4c3dc025ab4?source=rss-e7d22e79faf3------2</link>
            <guid isPermaLink="false">https://medium.com/p/c4c3dc025ab4</guid>
            <category><![CDATA[coronavirus]]></category>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[vaccines]]></category>
            <category><![CDATA[development]]></category>
            <category><![CDATA[global]]></category>
            <dc:creator><![CDATA[CUBE @UCLA]]></dc:creator>
            <pubDate>Mon, 25 May 2020 06:41:50 GMT</pubDate>
            <atom:updated>2020-05-25T06:41:50.201Z</atom:updated>
            <content:encoded><![CDATA[<h4>Vaccine Development, current clinical evaluation and a global landscape of collaboration and competition</h4><p>By Emily Mao</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*drHhpkmnmP2298AnfIcaCg.jpeg" /><figcaption>Source: <a href="https://www.health.harvard.edu/staying-healthy/are-there-any-new-vaccines">www.health.harvard.edu</a></figcaption></figure><p>COVID-19 pandemic has completely changed our lives. With international travel restrictions, stay-at-home orders, closed businesses, and so much more, it is difficult to see when we will resume our typical daily lives and when the economy can resume full activity. With experts such as Dr. Anthony Fauci, a top advisor to the White House and Department of Health and Human Services, <a href="https://www.usatoday.com/story/news/politics/2020/05/12/coronavirus-fauci-vaccine-timing-during-senate-hearing/3117915001/">dismissing</a> the possibility that the virus will disappear without a vaccine, the development and distribution of a vaccine, or multiple, is crucial. A worldwide hunt for a vaccine is undergoing.</p><h3><strong>Vaccine Development</strong></h3><p>The <a href="https://www.cdc.gov/vaccines/vpd/vpd-vac-basics.html">basic principle</a> of vaccines is simple. A person is exposed to killed or greatly weakened elements that cause the disease, and the immune system is stimulated to produce antibodies. Unlike other products that treat or cure a disease, vaccines <em>prevent</em> diseases by building immunity.</p><p>The technology to develop vaccines has shifted in recent years. The traditional tactic is a “one bug, one drug” approach. However, the emergence of platform technologies has garnered great attention. A platform is a technology that can be used to develop multiple vaccines; “they are pluripotent.” As a <a href="https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines">report</a> by Johns Hopkins’ Center for Health Security stresses, vaccine platforms can “speed development of vaccines for global catastrophic biologic risks and emerging infectious disease outbreaks.” Of the current COVID-19 candidate vaccines, many use the same platform as candidate vaccines for other diseases such as SARS and Ebola. This foundation has contributed to the confidence that a coronavirus vaccine can be developed faster than any precedent.</p><p><a href="https://www.centerforhealthsecurity.org/news/center-news/2019/2019-04-25-vaccine-platform.html">New report reviews the promise and challenges of vaccine platform technologies</a></p><p>While the technology for vaccine development has changed recently, the <a href="https://publichealthonline.gwu.edu/blog/producing-prevention-the-complex-development-of-vaccines/">process</a> of development is standard.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/768/1*M9kY8B97xn0tUL5---pUCQ.jpeg" /><figcaption>Source: <a href="https://publichealthonline.gwu.edu/blog/producing-prevention-the-complex-development-of-vaccines/">www.publichealthonline.gwu.edu</a></figcaption></figure><ul><li><strong>Exploratory</strong>: research-intensive phase to identify potential antigens, a substance that induces an immune response by the body</li><li><strong>Pre-Clinical</strong>: researchers test on tissue or cell cultures and animals to determine if immunity is produced and if there are no harmful effects</li><li><strong>Clinical Development</strong>: researchers conduct three phases of clinical trials</li><li><em>Phase I</em>: a small group (less than 100 people) and focuses on the safety and provoked responses</li><li><em>Phase II</em>: hundreds of people and seeks to provide more information on safety, immunization schedule, dose size, and ability to provoke an immune response</li><li><em>Phase III</em>: thousands of people and measures safety and effectiveness</li><li><strong>Regulatory Review &amp; Approval</strong>: developer submits a Biologics License Application (BLA) to the FDA in the United States</li><li><strong>Manufacturing</strong>: drug manufacturers create mass quantities of the vaccine and typically enjoy the profits</li><li><strong>Quality Control</strong>: vaccine’s performance, safety, and effectiveness continues to be tracked after approval distribution</li></ul><p>Historically, vaccine development is a long process, taking years and sometimes decades. However, the current situation has pressing urgency and research institutions are exploring various ways to try to shorten the timeline. First, institutions are using research from SARS and MERS, also caused by coronaviruses. This allows trials to start sooner, but may prove to decrease the success rate due to differences between previous viruses and COVID-19. Much hope lies in the sheer number of candidates since most candidates do not pass all phases, and having more horses starting the race increases the chance one makes it to the finish line. Companies and governments have also begun to anticipate the manufacturing phase by building more factories. An ideal situation would consist of multiple successful vaccines, easing worries over<strong> </strong>corporate or national interests along with production and distribution logistics.</p><p>As of May 15th, 2020, the <a href="https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines">World Health Organization</a> (WHO) tallies 8 candidate vaccines in clinical evaluation and 102 candidates in preclinical evaluation.</p><p><a href="https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines">Draft landscape of COVID-19 candidate vaccines</a></p><h3><strong>COVID-19 Candidate Vaccines Currently in Clinical Evaluation</strong></h3><h4>United States</h4><ul><li><strong><em>Moderna &amp; National Institute of Allergy and Infectious Diseases</em></strong></li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/620/1*7hldEH_oCkD2kYZ3P8nIdw.jpeg" /><figcaption>Source: <a href="https://www.wsj.com/articles/modernas-vaccine-hope-11589835889">www.wsj.com</a></figcaption></figure><p>Based in Cambridge, Massachusetts, <a href="https://time.com/5835785/moderna-coronavirus-vaccine-phase-2/">Moderna Therapeutics</a> is developing the U.S.’s first candidate vaccine to enter phase I and phase II of trials. Beginning its phase I trial on March 16th in three different states, the company already has plans to launch the final stage, phase III, this summer. The American government highly values this candidate, granting it fast-track approval from the US Food and Drug Administration (FDA) on May 12th. This means that the “agency can review data on a rolling basis”, ensuring that the entire approval application is not waiting for the final piece of data to be collected and analyzed. On May 18th, Moderna announced promising <a href="https://www.nytimes.com/2020/05/18/health/coronavirus-vaccine-moderna.html">preliminary findings</a> that its candidate vaccine appears safe and able to stimulate an immune response. The company’s stock soared from $66.69 to $86.28 following this news, and the <em>S&amp;P 500 rose more than three percent</em>, reflecting higher hope in a sooner return to normal.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*tz6gKrRyn5JdQrhCX16MBQ.png" /><figcaption>Source: Motley Fool</figcaption></figure><ul><li><strong><em>Inovio Pharmaceuticals</em></strong></li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/1000/1*u_p1PyunLBW7in7gj5kwEg.png" /><figcaption>Source: <a href="http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIOs-COVID-19-DNA-Vaccine-INO-4800-Demonstrates-Robust-Neutralizing-Antibody-and-T-Cell-Immune-Responses-in-Preclinical-Models/default.aspx">www.inovio.com</a></figcaption></figure><p>A COVID-19 vaccine candidate has entered this American biopharmaceutical company’s <a href="https://www.inovio.com/dna-medicines-pipeline/">pipeline</a>. It utilizes the same platform as the other multiple vaccine candidates in the company’s pipeline. With phase I starting on April 3rd and research in Missouri and Pennsylvania, the business is noteworthy for its enormous financial shifts prior to the trial. After the <a href="http://ir.inovio.com/news-releases/news-releases-details/2020/Inovio-Selected-by-CEPI-to-Develop-Vaccine-Against-New-Coronavirus/default.aspx">announcement</a> that Inovio was selected to receive a $9 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a coronavirus vaccine, it sold more than 43 million shares between January 1st and March 11th and has made <a href="https://www.statnews.com/2020/03/13/how-one-company-made-208-million-on-an-untested-coronavirus-vaccine/">$208 million</a> prior to human testing.</p><h4>China</h4><ul><li><strong><em>Wuhan Institute of Biological Products of Sinopharm</em></strong></li></ul><p>A candidate vaccine was registered for phase I/II testing on <a href="http://www.chictr.org.cn/showprojen.aspx?proj=52227">April 11th</a>, and the research for this immunization is occurring in He’nan, the neighboring province to Hubei. Sinopharm, formally known as China National Pharmaceutical Group, is a state-owned enterprise. It is the second-largest pharmaceutical company in China in terms of revenue, ranking at <a href="https://fortune.com/global500/2019/sinopharm/">169</a> on 2019’s Fortune Global 500.</p><ul><li><strong><em>Beijing Institute of Biological Products of Sinopharm</em></strong></li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/224/1*7iULRfsDps4UDC-RMsYKAQ.jpeg" /><figcaption>Source:<a href="https://www.facebook.com/pg/APIHUBEI/posts/"> www.facebook.com</a></figcaption></figure><p>Registering for phase I/II on <a href="http://www.chictr.org.cn/showproj.aspx?proj=53003">April 29th</a>, this candidate is also conducting research in the He’nan province. It is also developed by Sinopharm, making Sinopharm the only company with two different candidates in clinical evaluation.</p><ul><li><strong><em>Sinovac</em></strong></li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/620/1*j8GE2dOf5M9ZNC7o4VhpTA.jpeg" /><figcaption>Source: <a href="https://desktop.gulf-times.com/story/663247/China-has-five-virus-vaccines-in-human-trials-offi">www.gulf-times.com</a></figcaption></figure><p>A China-based pharmaceutical company, Sinovac started phase I/II trials on <a href="https://clinicaltrials.gov/ct2/show/NCT04352608?term=Sinovac&amp;cntry=CN&amp;draw=2">April 16th</a> utilizing the same platform as a SARS vaccine candidate. Research is being conducted in the Jiangsu province. The company obtained an $8.5 million USD loan from the Bank of Beijing and more than 70,000 square meters of land for the <a href="https://www.nasdaq.com/articles/chinas-sinovac-gains-land-and-loans-to-speed-up-work-on-coronavirus-vaccine-2020-04-23">plan</a> of a new production facility.</p><h4>United Kingdom</h4><ul><li><strong><em>University of Oxford</em></strong></li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*dVR8eK1Y-fw_8nPPsgqgHQ.jpeg" /><figcaption>Source: <a href="https://www.ox.ac.uk/coronavirus/advice?wssl=1">ox.au.uk</a></figcaption></figure><p>This candidate vaccine entered phase I/II on <a href="https://clinicaltrials.gov/ct2/show/NCT04324606?term=vaccine&amp;cond=covid-19&amp;draw=2">April 23rd</a> and utilizes the same platform as candidate vaccines for MERS, influenza, Zika, and several other infectious diseases. On April 30th, the University of Oxford announced a <a href="https://www.ovg.ox.ac.uk/news/landmark-partnership-announced-for-development-of-covid-19-vaccine">partnership</a> with AstraZeneca, a UK-based biopharmaceutical company, for further development and larger-scale manufacturing. In this agreement, both bodies agreed to work on the international distribution of the vaccine, particularly on availability and accessibility for low and medium-income countries. This collaboration is also notable for the decision to operate on a not-for-profit basis during the coronavirus pandemic, covering only the costs for production and distribution.</p><h4>International</h4><ul><li><strong><em>BioNTech, Pfizer, &amp; Fosun</em></strong></li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/962/1*KZI0jrwqM0iWZgFz9VSkmA.jpeg" /><figcaption>Source:<a href="https://www.contractpharma.com/contents/view_breaking-news/2020-03-16/biontech-reports-progress-on-covid-19-vaccine-program/"> www.contractpharma.com</a></figcaption></figure><p>BioNTech, a German company, and Pfizer, an American company, have teamed up to develop a COVID-19 vaccine. Phase I/II of the study began on <a href="https://clinicaltrials.gov/ct2/show/NCT04368728?term=vaccine&amp;cond=covid-19&amp;draw=3">April 29th</a>, with cohorts in both the US and Germany receiving candidate vaccine injections as part of their global clinical development program. They plan to follow this program with the activation of their extensive manufacturing network in hopes to produce a global supply. Although their partnership for the commercialization of a vaccine will not extend to China, BioNTech is collaborating separately with Fosun Pharma, a Chinese company. Conditions of this <a href="https://www.fosunpharma.com/en/news/news-details-3801.html">alliance</a> include Fosun paying BioNTech up to $85 million in licensing fees along with a sales commission equal to 35% of gross profit. Fosun will also be making an equity investment of $50 million in BioNTech.</p><ul><li><strong><em>CanSino Biological Inc. &amp; National Research Council of Canada</em></strong></li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/730/1*l6EBXuWfiHSNeleVR9BDFQ.jpeg" /><figcaption>Source: <a href="https://www.nextbigfuture.com/2020/04/cansino-biologics-has-first-covid-19-vaccine-to-reach-phase-2.html">www.nextbigfuture.com</a></figcaption></figure><p>The first candidate in the world to enter <a href="http://www.chictr.org.cn/showprojen.aspx?proj=52006">phase II</a> of clinical evaluation on April 10th uses the same platform as an ebola vaccine candidate. CanSino is working in alliance with the Chinese government-backed Institute of Biotechnology. The research is being conducted in Wuhan, China, the place first hit by this world-wide pandemic. This candidate will also conduct future clinical trials in Canada, a <a href="https://www.canada.ca/en/national-research-council/news/2020/05/the-national-research-council-of-canada-and-cansino-biologics-inc-announce-collaboration-to-advance-vaccine-against-covid-19.html">collaboration</a> announced by the National Research Council of Canada (NRC) on May 12th. The relationship between the two entities began in 2013 when a cell line developed by the NRC was licensed to CanSino, becoming part of their platform. Given its front-running standing and global collaboration, CanSino Biological Inc., has seen tremendous increase in its stock price. Valued at $7.50 USD at the start of this year, its current price now is at $22.40 USD as of May 12th.</p><h3><strong>A Global Landscape of Collaboration and Competition</strong></h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*RHPwX1VZh17wDsh_ZJ6Igw.jpeg" /><figcaption>Source: <a href="https://www.rtmagazine.com/disorders-diseases/infectious-diseases/other-infections/these-34-countries-confirmed-covid-19-this-week/">www.rtmagazine.com</a></figcaption></figure><p>An unprecedented global pandemic has sparked unprecedented collaboration between nations. Beginning with the <a href="https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/">publishing</a> of the SARS-CoV-2 genetic sequence from Chinese scientists at the end of 2019, a worldwide effort is proceeding. The World Health Organization has <a href="https://www.who.int/news-room/detail/13-04-2020-public-statement-for-collaboration-on-covid-19-vaccine-development">coordinated</a> scientists, physicians, funders, and manufacturers of diverse backgrounds to work on the development of a vaccine. The sharing of data and international alliances between companies and research institutes are great strides to pool resources together for the development and manufacturing of vaccines.</p><p>While there is great global collaboration, the sense of competition between nations is undeniable. The <a href="https://www.nytimes.com/2020/03/19/us/politics/coronavirus-vaccine-competition.html">nationalistic</a> approach stems from the simple idea that the winner has the chance to favor its own population and gain the advantage in economic recovery. The Trump administration attempted to persuade a German company, <a href="https://www.nytimes.com/2020/03/15/world/europe/cornonavirus-vaccine-us-germany.html">CureVac</a>, into moving its research to the United States. Fosun, a Chinese pharmaceutical company, successfully offered BioNTech, a German company, $135 million for a strategic alliance within Chinese borders.</p><p>International collaboration is beneficial for the development of a successful vaccine, but the sense of competition will ultimately shape the world after a vaccine has been proven safe and effective. With limited manufacturing and a global demand, <em>accessibility and affordability</em> will continue to be issues that define healthcare and the post-pandemic world.</p><p><em>Emily Mao is a Business Economics &amp; Human Biology and Society double major at UCLA, from Chicago, IL. Emily focuses her article on the search for a vaccine for COVID-19. To her, this topic is interesting for its crucial role in ending this pandemic and for its unprecedented impacts on biotech companies, institutions, and the dynamic between them.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=c4c3dc025ab4" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Tracking 3 of the World’s Largest Biotechnology Stocks during COVID-19]]></title>
            <link>https://medium.com/@cube.ucla/tracking-3-of-the-worlds-largest-biotechnology-stocks-during-covid-19-fbfca45c9412?source=rss-e7d22e79faf3------2</link>
            <guid isPermaLink="false">https://medium.com/p/fbfca45c9412</guid>
            <category><![CDATA[healthcare-technology]]></category>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[stocks]]></category>
            <category><![CDATA[business]]></category>
            <category><![CDATA[biotechnology]]></category>
            <dc:creator><![CDATA[CUBE @UCLA]]></dc:creator>
            <pubDate>Sat, 23 May 2020 10:51:21 GMT</pubDate>
            <atom:updated>2020-05-25T06:55:09.062Z</atom:updated>
            <content:encoded><![CDATA[<h4>Stock Performances of Amgen, Gilead Sciences and Vertex Pharmaceuticals in the midst of combatting the pandemic</h4><p>By Rahil Modi</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*0zGwKAUfdBMR13vo1GAxOQ.png" /><figcaption>Source: CU Management</figcaption></figure><p>The novel coronavirus known as COVID-19 has upended daily life as we know it. Public spaces have been closed, economies have grinded to a halt, and the healthcare system has been placed under immense pressure. According to the U.S. Labor Department, <strong>38.6 million people</strong> filed for unemployment over the last nine weeks, raising the <strong>unemployment rate to 17.2% — a level not seen since the Great Depression.</strong> This statistic has greatly increased concern for the United States’ long-term economic future, causing clamors to reopen the country. Despite the economic downturn and the healthcare crisis, the biotechnology sector has an unparalleled opportunity for growth. Examining three of the largest biotechnology companies, <strong>Amgen Inc., Gilead Sciences Inc., and Vertex Pharmaceuticals</strong>, can provide some helpful insight into how the industry is faring during these unprecedented times.</p><h3><strong>Amgen Inc. (AMGN)</strong></h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*WzlQgwrQeO8_sIVX" /><figcaption>Source: Motley Fool</figcaption></figure><p>Amgen is a biotechnology company that focuses on developing medicines for diseases that currently have limited treatment options. They mainly focus on six areas: cardiovascular disease, oncology, bone health, nephrology, neuroscience, and inflammation. Some of their most impactful drugs include Neupogen (treats low white blood cell counts), Vectibix (treats colon cancer), and Evenity (treats postmenopausal osteoporosis).</p><p>These innovations did not make Amgen immune to the effects of the coronavirus. From the beginning of February until mid-March, <strong>Amgen’s value decreased by 13% (from 216.88 to 188.68).</strong> This dramatic decrease can definitely be attributed to the rise of coronavirus cases in the United States, and the sharper decline that can be seen in early to mid-March is due to the official declaration of COVID-19 as a pandemic.</p><p>In early April, Amgen announced a partnership with Adaptive Biotechnologies to develop antibodies utilizing their respective expertise in antibody therapy development and antibody identification. Adaptive’s identification platform screens the B cell receptors of recovered individuals, allowing them to detect thousands of natural antibodies. From these antibodies, according to Genetic Engineering and Biotechnology News, Amgen will select and develop antibodies specifically to neutralize SARS-CoV-2. This project, in conjunction with an uninterrupted supply of Amgen’s current treatments, has boosted Amgen’s value in the last month. However, it is reasonable to expect fluctuations due to a delay in some diagnoses and treatments.</p><p>Another factor contributing to Amgen’s growth since mid-March is Otezla, a drug used to treat moderate-to-severe psoriasis. On May 6, the company announced that in a phase 3 clinical trial, <strong>mild-to-moderate psoriasis patients demonstrated 75% improvement in response to the drug</strong>, meaning that their skin was almost clear. Additionally, clinical trials to test Otezla’s effectiveness against COVID-19 are to begin in the coming weeks, boosting sales optimism in 2020.</p><p><a href="https://www.fiercepharma.com/pharma/amgen-ramps-up-otezla-expansion-effort-positive-data-mild-psoriasis">Amgen ramps up Otezla expansion effort with positive data in mild psoriasis</a></p><h3><strong>Gilead Sciences Inc. (GILD)</strong></h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*dyiqnOTzKcD-8lGx" /><figcaption>Source: Motley Fool</figcaption></figure><p>Gilead, a biopharmaceutical company, develops primarily antiviral drugs used to treat influenza, HIV, and hepatitis C. They are currently developing a drug named Remdesivir that was originally developed to treat Ebola but is now being repurposed to treat coronavirus. A study conducted by the National Institutes of Health demonstrated that <strong>COVID-19 patients who took Remdesivir recovered 31% faster than those who took a placebo.</strong> These results cleared the path for the Food and Drug Administration to approve the emergency use of the drug to treat COVID-19 patients on a much wider scale.</p><p>Remdesivir’s potential explains why, <strong>from February through early May, Gilead’s value has increased by 20.5% (from 66.36 to 79.95).</strong> However, despite Gilead’s swift efforts in addressing COVID-19, many investors are not sold on Remdesivir’s ability to sustain a steady revenue stream in the long term. In fact, J.P. Morgan and SunTrust Robinson Humphrey downgraded Gilead’s stock from “overweight” to “neutral” and “hold” to “sell” respectively, indicating the immense skepticism among investors of Remdesivir’s long-term potential. <strong>This skepticism certainly contributed to the</strong> <strong>recent 8.8% decline in Gilead’s value (from 79.95 to 73.50).</strong></p><p><a href="https://www.cnbc.com/2020/05/01/gilead-gets-emergency-fda-authorization-for-remdesivir-to-treat-coronavirus-trump-says.html">Gilead gets emergency FDA authorization for remdesivir to treat coronavirus, Trump says</a></p><h3><strong>Vertex Pharmaceuticals (VRTX)</strong></h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*sBVG5yTW7q99T6Jq" /><figcaption>Source: Motley Fool</figcaption></figure><p>Vertex Pharmaceuticals is a biotechnology company that aims to understand the underlying mechanisms of various life-threatening diseases and develops treatments to aid patients suffering from these diseases. They are most well-known for developing the first treatment for the underlying cause of cystic fibrosis.</p><p>From the beginning of February until mid-March, Vertex Pharmaceuticals experienced a decrease in its market value by 13.3% (from 230.51 to 199.77). <strong>Since March 16, Vertex has increased its value by 42.5%</strong>, <strong>currently sitting at 284.63.</strong> According to the newly appointed CEO, Reshma Kewalramani, Vertex’s first-quarter revenues increased by 77% compared to 2019. Kewalramani attributed this increase to the successful launch of TRIKAFTA, a breakthrough treatment for cystic fibrosis. Additionally, COVID-19 has not disrupted the supply chain for this treatment, increasing overall optimism for the company in worldwide distribution of this treatment throughout 2020.</p><p><a href="https://www.businesswire.com/news/home/20200429005528/en/Vertex-Reports-First-Quarter-2020-Financial-Results">Vertex Reports First-Quarter 2020 Financial Results</a></p><p><em>Rahil Modi is a Computational and Systems Biology major at UCLA from Savage, MN. Rahil is interested in healthcare stock performances where he can learn about some of the healthcare industry’s biggest players and what things they’ve done recently. He has also started investing and tracking stocks, allowing him to build upon that knowledge.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=fbfca45c9412" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Tuberculosis — A Fight to the Finish Line.]]></title>
            <link>https://medium.com/@cube.ucla/tuberculosis-a-fight-to-the-finish-line-368e09de0?source=rss-e7d22e79faf3------2</link>
            <guid isPermaLink="false">https://medium.com/p/368e09de0</guid>
            <category><![CDATA[tuberculosis]]></category>
            <category><![CDATA[infectious-disease]]></category>
            <category><![CDATA[social-factors]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[poverty]]></category>
            <dc:creator><![CDATA[CUBE @UCLA]]></dc:creator>
            <pubDate>Fri, 22 May 2020 05:15:27 GMT</pubDate>
            <atom:updated>2020-07-08T16:31:27.924Z</atom:updated>
            <content:encoded><![CDATA[<h3>Tuberculosis — A Fight to the Finish Line</h3><h4><em>Looking into disparities, prevalence, and pathway to eradication.</em></h4><p>By Ayushi Bommireddipalli</p><h3><strong>Infectious Diseases — Tuberculosis</strong></h3><p>As human beings living on a planet with such diversity not just among us, but also amidst nature, we are exposed to a plethora of different microorganisms, animals, plants, and bacteria. In light of the recent pandemic, the discussion of infectious, and contagious diseases has especially come about. “An infection is a disease caused by pathogenic microorganisms, such as bacteria, viruses, parasites or fungi, that can be spread, directly or indirectly from one person to another”</p><p>Tuberculosis (TB) is a disease caused by bacteria <em>Mycobacterium tuberculosis,</em> which is contagious and airborne. Over the years, tuberculosis has infected and caused the death of millions of people, from infants to the elderly. The disease primarily affects the lungs and is called Pulmonary Tuberculosis, but it is also known to have affected the intestine, meninges, bones and joints, lymph glands, skin, and other tissues in the body. The symptoms for tuberculosis include a bad, long-lasting cough, pain in the chest, weakness, weight loss and loss of appetite, chills, fever, and sweating.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/30212088/">Tuberculosis - PubMed</a></p><p>While our body’s defense, the immune system, has an army of T cells, phagocytes, and other “soldiers” that can help fight the infectious bacteria by either engulfing them or preventing them from entering the body altogether, certain infectious diseases, such as Tuberculosis are still prevalent and continue to affect one-third of the total world population.</p><p><a href="https://www.who.int/health-topics/tuberculosis#tab=tab_1">Tuberculosis</a></p><h4><strong>The disparity in the Burden of Tuberculosis</strong></h4><p>The countries with the highest burden of TB are India, Indonesia, China, Nigeria, Pakistan, Bangladesh, Ethiopia, Kenya, Thailand. A truly significant factor amongst these countries is that they are all in Stage 1 of the Epidemiological Transition Model i.e these are developing or under-developed countries where the major cause of mortality is infectious diseases that primarily affect the respiratory system. (source: WHO, NCBI)</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/708/1*sJuDFOP1-oiG3khrRSjImg.jpeg" /></figure><p>The countries majorly dealing with Tuberculosis have a majority of the population that is under the poverty level, which brings upon an interesting point of a certain section of society that feels the effect of this fatal bacteria more than others. It is no coincidence that the countries most affected by the bacteria, are ones that are facing extreme poverty, and have social inequalities more prevalent than other nations. TB tends to impact the poorest people mainly for instance, because of the social conditions they work in, bringing us to the point of the modifiable risk factors of this disease.</p><p><em>In an article published by Olivia Oxlade and Megan Murray, they discuss how poverty is an important risk factor in the incidence of tuberculosis in India.</em></p><p>The experiment conducted assessed the determinants and socio-economic status of the self-reported tuberculosis cases. The results established certain risk factors that are largely common in people of lower-income, under the poverty level. <strong>The Population Attributable Fraction (PAF) of tuberculosis was 34.2% for people with low Body Mass Index (BMI)</strong> and <strong>28.5% for people highly exposed to indoor air pollution.</strong> This proved that factors like low BMI and indoor air-pollution have a large mediating effect on the relation between TB prevalence, and poverty. (source: NCBI)</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/890/1*CUogDR_ExRL0ECvPgT58QQ.png" /><figcaption>Source: Tuberculosis and Poverty: Why are the Poor at Greater Risk in India?</figcaption></figure><p>A very important realization one must come to when talking about Tuberculosis and its prevalence is the fact that <em>this issue is just as much of a social one, as it is biological</em>. While the fact of the matter is, that the tuberculosis bacteria actively multiplies when it enters the host (humans) and can fight and eventually win over a compromised immune system, one must ask, what is leading to these compromised immune systems? And why is it that these compromised immune systems happen to be of people of the lower-income class? It just happens to be, that these infected people are exposed to the very easily modifiable risk factors such as unclean air, lack of hygiene in the workplace, stagnant water, and most importantly: lack of accessibility to healthcare, which is a shortcoming of the global healthcare system.</p><p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501509/">Tuberculosis and Poverty: Why Are the Poor at Greater Risk in India?</a></p><p><strong>The annual decline of TB is 1.2%</strong> when it definitely should be higher, given the resources, the medical inventions, and science. Yet, lower-income countries still face the deathly hallows of this disease. While many measures are being taken to treat tuberculosis, what really needs the utmost attention of the healthcare system is the primary prevention of this disease in the lower-income population specifically. This can be done by modifying the risk factors that cause this disease in the first place.</p><p>According to the United Nations, the first step towards improving the living conditions of the poor is improving the public health policies in lower-income countries. These policies must ensure that sanitation, housing, and clean water, air, and working conditions are ensured for people of the lower economic strata, who are also daily wage workers at construction sites, restaurants, and other places with a high risk of bacterial exposure. Routine checks of these places must be done to ensure that the workers are well-equipped and not exposed to air pollution in an amount that makes them susceptible to tuberculosis.</p><h4>Pathways to Prevention</h4><p>Another important part of primary prevention of TB is accessibility to the BCG vaccination. Many countries like India have a National Immunization Scheme (1985) that provides accessibility to vaccination for newborns at a nominal rate, which decreases the incidence of infant tuberculosis. This vaccination can only be given in the first 12 months of being born and only protects against infant tuberculosis but may reduce the complications if contracted later in life. Many daily wagers born before the scheme was put into place, or born through midwives or at home, and who are religiously exposed to TB risk factors have not been immunized. A very simple answer to this would be ‘<em>education’</em>. Education of healthcare professionals, education of those at risk, education for the diagnosis, prevention, and for the cure. Running educational campaigns on a world-wide basis that specifically address tuberculosis and are aimed at not just healthcare professionals, but also migrant workers, people below the poverty line, and new mothers who have infants at high risk for TB, will surely be a good move to fasten the process of TB eradication. Educational workshops that talk about how the risk factors can be modified enough to at least, try to prevent the disease, will be a baby step towards eradication of the disease altogether.</p><p>The next method of TB eradication is focusing on the tertiary prevention of the disease, which involves medication and treatment on contracting the disease. According to the CDC, <strong>direct costs averaged $134,000 per multi-drug resistant TB patient, and $430,000 per extensively resistant TB patient, and $17,000 per normal TB patient</strong>. <strong>It costs 13,500 rupees to treat a normal case of TB in India.</strong> A normal daily wage worker earns less than 5000 rupees a month, and cannot cover the cost of disease treatment (source: Economic Times India). In such a circumstance, it is of prime importance that the Government and the healthcare sector provides some support to the lower-income class, in order to relieve their financial burden and also lower the mortality rate.</p><p><a href="https://www.cdc.gov/tb/default.htm">Tuberculosis (TB)</a></p><blockquote>Dr. Margaret Chan, Director General of the WHO, made the following call when announcing the ambitious End TB strategy: “Everyone with TB should have access to the innovative tools and services they need for rapid diagnosis, treatment and care. This is a matter of social justice, fundamental to our goal of universal health coverage. Given the prevalence of drug-resistant tuberculosis, ensuring high quality and complete care will also benefit global health security.” (source: International Journal of Infectious Diseases)</blockquote><p>The fact of the matter is, a lot has been done by NGOs like InSTEDD that use modern technology to help diagnose TB symptoms and ensure the treatment to help eradicate this disease, and we can in no measure ignore or undermine that. In fact, an “End TB Strategy” has been put into force by the WHO to ensure that enough measures are being taken to fight this disease to the finish line. But somehow, we still fall short at a societal level. The problem is not what has been done, it is; how it is being done and to what extent.</p><p>While treatment and medication are available, it is not <strong>accessible</strong>, and that is what the healthcare industry can focus on — <em>accessibility.</em></p><p><em>Ayushi Bommireddipalli is a Molecular, Cell, and Developmental Biology major at UCLA. She is an international student who passionately believes in accessibility to health care, believing it to have a difference globally. In addition to healthcare, Ayushi loves biology, dance, and travel.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=368e09de0" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Decrease in Domestic Abuse Cases in the United States during Covid-19?]]></title>
            <link>https://medium.com/@cube.ucla/decrease-in-domestic-abuse-cases-in-the-united-states-during-covid-19-b6752373644d?source=rss-e7d22e79faf3------2</link>
            <guid isPermaLink="false">https://medium.com/p/b6752373644d</guid>
            <dc:creator><![CDATA[CUBE @UCLA]]></dc:creator>
            <pubDate>Fri, 22 May 2020 04:28:54 GMT</pubDate>
            <atom:updated>2020-05-25T06:53:59.039Z</atom:updated>
            <content:encoded><![CDATA[<h4>Domestic Violence, Barriers from Seeking Aid During a Pandemic, and how you can help.</h4><p>By Maria John</p><blockquote>trigger warning: this article discusses various aspects of domestic abuse and crimes surrounding it</blockquote><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*rD9KAwpyXKkOd1D3.jpg" /><figcaption>Source: UVA today</figcaption></figure><p>Imagine a life where you live in fear of abuse by your husband and daily activities such as going to work, and getting groceries was just enough to stop yourself from running away or taking your life. Once the news of Covid-19 hits, your heart sinks and you feel like you can’t breathe because your avenues of relief are taken away from you. Victims of domestic abuse already suffered before the onset of Covid-19 and although there are more limitations to receiving help there is a decrease in the overall cases of domestic violence. The US Department of Justice claims that <strong>1.3 million women and 835,000 men fall victim to domestic abuse every year</strong>. But after the global pandemic hit and forced us into our homes we expected the amount to increase even more. Surprisingly, the data shows otherwise.</p><p><a href="https://www.nbcnews.com/news/us-news/police-see-rise-domestic-violence-calls-amid-coronavirus-lockdown-n1176151">Domestic violence calls increase amid coronavirus lockdown, police say</a></p><p><strong>So why does data show that domestic violence rates have decreased compared to past years?</strong></p><p>According to the Bureau of Justice, <strong>only half the domestic abuse cases usually got reported</strong> before the pandemic hit. After the announcement of Covid-19, it became difficult to determine the number of cases due to the underreporting attributed to the increased barriers the pandemic had caused. Overall, both the crime rate and the number of domestic violence cases decreased. Although the domestic violence rate decreased it is still higher than the crime rates and there are researched claims that show that it is likely that many of the domestic abuse cases are being masked as criminal cases.</p><blockquote>This image was taken from the Marshall project and shows the increased decrease in crime rates compared to the decrease in domestic abuse cases.</blockquote><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*ERwhQMZqBNJvrqx-aORHvg.png" /></figure><p>The Marshall Project, non-profit journalism on criminal justice, has researched a way to decipher the gaps in underreporting by comparing police incident reports and domestic abuse reports. Based on their research in the cities of Chandler, Chicago, and Austin, they noticed the number of cases was in fact dropping. They also found that <strong>domestic service calls increased by 13% </strong>from the previous year even though the actual cases decreased. It was concluded that this could be because neighbors are calling to report abuse but victims are reluctant to follow through with the charges in fear of their abusers. In addition, even though domestic violence cases are reported as decreasing, the severity of the reported cases are increasing.</p><p><a href="https://www.themarshallproject.org/2020/04/22/is-domestic-violence-rising-during-the-coronavirus-shutdown-here-s-what-the-data-shows">Is Domestic Violence Rising During the Coronavirus Shutdown? Here&#39;s What the Data Shows.</a></p><p>The Marshall Project reported that the domestic violence-related crimes in the month of March and the first two weeks of April were<strong> three murders and 78 shootings </strong>which were an increase from the year before. In addition, even though domestic violence cases are reported as decreasing, the severity of the reported cases are increasing. This evidence shows how <strong>domestic violence rates can be hidden under the shadow of crime rates.</strong></p><p><a href="https://data.cityofchicago.org/Public-Safety/Crimes-2001-to-present/ijzp-q8t2">Crimes - 2001 to present | City of Chicago | Data Portal</a></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/290/0*Tn-BjC-vDUXCmTvX" /></figure><p><a href="https://data.austintexas.gov/Public-Safety/Crime-Reports/fdj4-gpfu">Crime Reports | Open Data | City of Austin Texas</a></p><p><strong>What are the barriers that prevent individuals from seeking help?</strong></p><p>The Covid-19 pandemic has hit many marginalized communities hard, but the victims of domestic abuse are often silenced in their homes suffering helplessly. There are infinite barriers that prevent them from seeking and receiving help which could be a factor in why the reported cases are decreasing.</p><h4>Limitations preventing victims from getting help</h4><ul><li>According to the National Coalition Against Domestic Violence, some fear that if they leave, they will ruin their children’s lives and others don’t leave because they would be homeless if they did.</li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/275/0*qwk_zqyjLbiUCqeQ" /><figcaption>Source: Vox</figcaption></figure><ul><li>Victims also don’t leave because they are scared that the abusers will hurt them or their loved ones. In addition, there was a study done by the American Public Health Association that showed that 20% that ended up dead were family members and acquaintances, not the domestic abuse victims themselves.</li></ul><p><a href="https://ncadv.org/why-do-victims-stay">NCADV | National Coalition Against Domestic Violence</a></p><h4>Limitations to getting help specifically due to the pandemic</h4><ul><li>For some, leaving means moving into a shelter, but that could cause their children to contract the virus especially during this time when millions are losing their jobs.</li><li>Many domestic abuse calls come from the grocery store or from their place of work, and without that outlet being easily accessible, it creates more difficulty in getting help.</li></ul><p><strong>Are there ways the community or you personally can help?</strong></p><p>Although it is difficult to help these individuals we can create supports that are more discreet than outwardly calling the police. The director of Intimate Partner Violence Prevention Program at John Jay College of Criminal Justice’s National Network for Safe communities explained that since victims are calling the police as the last resort, we should increase the number of intermediate resources they can receive help such as making grocery markets and pharmacies places for meeting with advocates that can help domestic abuse victims. Although this is a tough time for citizens around the world it is important to keep victims of domestic violence in mind and call 911 in emergencies and if you suspect domestic violence. <strong>Also if you are in need of support please call 1–800–799–7233. If you are unable to speak safely log onto thehotline.org or text LOVEIS to 2252.</strong></p><p><a href="https://www.thehotline.org/">National Domestic Violence Hotline</a></p><p><em>Maria John is a Public Affairs major at UCLA from Sacramento, CA. Maria is specifically interested in health policy and the importance that our legislature plays in decisions about who is or isn’t receiving healthcare. She is keen to write about the rise in domestic abuse cases because the numbers are indeed shocking. By bringing this issue to light and sharing a few resources, she hopes her article could help people.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=b6752373644d" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>